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BACKGROUND
Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) 
inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein 
(LDL) cholesterol that result from their use are associated with cognitive deficits.
METHODS
In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab 
added to statin therapy, we prospectively assessed cognitive function using the Cambridge 
Neuropsychological Test Automated Battery. The primary end point was the score on the 
spatial working memory strategy index of executive function (scores range from 4 to 28, 
with lower scores indicating a more efficient use of strategy and planning). Secondary end 
points were the scores for working memory (scores range from 0 to 279, with lower scores 
indicating fewer errors), episodic memory (scores range from 0 to 70, with lower scores 
indicating fewer errors), and psychomotor speed (scores range from 100 to 5100 msec, 
with faster times representing better performance). Assessments of cognitive function 
were performed at baseline, week 24, yearly, and at the end of the trial. The primary 
analysis was a noninferiority comparison of the mean change from baseline in the score 
on the spatial working memory strategy index of executive function between the patients 
who received evolocumab and those who received placebo; the noninferiority margin was 
set at 20% of the standard deviation of the score in the placebo group.
RESULTS
A total of 1204 patients were followed for a median of 19 months; the mean (±SD) change 
from baseline over time in the raw score for the spatial working memory strategy index 
of executive function (primary end point) was −0.21±2.62 in the evolocumab group and 
−0.29±2.81 in the placebo group (P<0.001 for noninferiority; P = 0.85 for superiority). 
There were no significant between-group differences in the secondary end points of 
scores for working memory (change in raw score, −0.52 in the evolocumab group and 
−0.93 in the placebo group), episodic memory (change in raw score, −1.53 and −1.53, 
respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respec-
tively). In an exploratory analysis, there were no associations between LDL cholesterol 
levels and cognitive changes.
CONCLUSIONS
In a randomized trial involving patients who received either evolocumab or placebo in 
addition to statin therapy, no significant between-group difference in cognitive func-
tion was observed over a median of 19 months. (Funded by Amgen; EBBINGHAUS 
ClinicalTrials.gov number, NCT02207634.)
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Statin therapy,1 ezetimibe,2 and the proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab3 have been 
shown to reduce the rate of cardiovascular events 
among patients with established cardiovascular 
disease. These therapies may result in very low 
levels of low-density lipoprotein (LDL) cholesterol. 
Postmarketing surveillance reports, observational 
studies, and some small randomized trials of 
statin therapy4,5 have suggested that statins — or 
the low levels of LDL cholesterol that result from 
their use — may be associated with impaired 
cognitive function, which led the Food and Drug 
Administration to issue a warning in 2012.6 
However, it remains unclear whether the putative 
adverse effects of statins on cognitive function 
can be attributed to their effect of lowering LDL 
cholesterol level or to other effects unique to this 
class of drugs. For example, systematic reviews 
and meta-analyses have not shown consistent 
evidence of adverse effects of statins on cognition, 
and the Statin Cognitive Safety Task Force in 
2014 concluded that statins are not associated 
with these adverse effects.7 Furthermore, a re-
cent study that used eight neuropsychological 
measures and functional magnetic resonance 
imaging showed no convincing evidence of 
memory dysfunction as a result of atorvastatin 
therapy.8
Two moderately sized trials of PCSK9 inhibi-
tors for lowering LDL cholesterol level9,10 and a 
meta-analysis that included smaller trials11 showed 
an association between these drugs and cognitive 
adverse events reported by the patients. However, 
the incidence of these symptoms was less than 
1%, with broad confidence intervals around the 
observed hazard ratio. Published data from pro-
spective assessments of the effect of PCSK9 in-
hibitors on cognitive function that used vali-
dated instruments are lacking. In the Evaluating 
PCSK9 Binding Antibody Influence on Cognitive 
Health in High Cardiovascular Risk Subjects 
(EBBINGHAUS) study,12 we prospectively evaluat-
ed cognition using the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB, www 
. cambridgecognition . com) among patients who 
had been randomly assigned to receive either the 
PCSK9 inhibitor evolocumab or placebo in addi-
tion to statin therapy. These tests have been used 
in more than 160 clinical trials, in all phases of 
drug development, and with a broad range of 
medications; they are sensitive to both positive 
and negative effects of drugs on cognition.13-17
Me thods
Trial Design and Oversight
The EBBINGHAUS study involved a subgroup of 
patients from the Further Cardiovascular Out-
comes Research with PCSK9 Inhibition in Sub-
jects with Elevated Risk (FOURIER) trial, which 
evaluated the efficacy and safety of evolocumab 
for the reduction of LDL cholesterol level.3,18 An 
executive committee (for a list of committee 
members, see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org), Cambridge Cognition (the neuro-
science digital health company that developed 
CANTAB), and Amgen (the trial sponsor) col-
laborated in designing the trial.12 The protocol, 
available at NEJM.org, was approved by the 
ethics committee at each participating site. The 
sponsor was responsible for collection of the 
data and supplied the study drug and placebo. 
Members of the Thrombolysis in Myocardial In-
farction (TIMI) Study Group conducted all analy-
ses of the data independently of the sponsor. The 
first author wrote the first draft of the manu-
script, and all the coauthors participated in 
subsequent revisions. All the authors vouch for 
the accuracy and completeness of the data and 
analyses and for the fidelity of the study to the 
protocol.
Trial Population
The participants in the FOURIER trial3,18 were 
between 40 and 85 years of age, had clinically 
evident atherosclerosis and an LDL cholesterol 
level of 70 mg per deciliter (1.8 mmol per liter) 
or higher or a non–high-density lipoprotein level 
of 100 mg per deciliter (2.6 mmol per liter) or 
higher, and were receiving moderate-intensity or 
high-intensity statin therapy. The participating 
centers in 29 countries were encouraged to en-
roll patients in the EBBINGHAUS study before 
the administration of the first dose of the study 
drug or placebo in the FOURIER trial, although 
enrollment was permitted until the 12-week visit 
in the FOURIER trial. Exclusion criteria were 
current or past diagnosis of dementia or mild 
cognitive impairment or any condition or situ-
ation, including other mental or neurologic disor-
ders, that, in the investigator’s opinion, could 
confound the study results or considerably inter-
fere with the patient’s participation in the trial. 
All the patients provided written informed 
consent.
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Randomization and Study Groups
Patients in the FOURIER trial were randomly 
assigned, in a 1:1 ratio, to receive subcutaneous 
evolocumab (140 mg every 2 weeks or 420 mg 
every month, according to patient preference) or 
to receive matching placebo. Double-blind ran-
domization was performed with the use of a 
central, 24-hour, interactive, computerized re-
sponse system, with stratification according to 
region and final screening LDL cholesterol level 
(<85 mg per deciliter [2.2 mmol per liter] or 
≥85 mg per deciliter).
End Points
The primary end point was the score on the 
spatial working memory strategy index of execu-
tive function, a principal component of CANTAB; 
CANTAB was performed at screening (training 
session), at baseline, at 24 weeks, yearly, and 
at the end of the trial. CANTAB is a language-
independent and culture-independent computer-
ized cognitive assessment tool that uses touch-
screen neuropsychological tests of cognition that 
are specifically designed to assess central nervous 
system disorders and cognitive function across a 
range of domains, including episodic and working 
memory, executive function, psychomotor speed, 
and attention (further details of CANTAB are 
provided in the Supplementary Appendix). The 
score on the spatial working memory strategy 
index of executive function indicates the number 
of times a patient begins a search with a differ-
ent box than the one used to begin the search in 
the previous search sequence, across a total of 
four rounds of testing that have six or eight boxes 
(scores range from 4 to 28, with lower scores 
representing a more efficient use of strategy and 
planning).
The three secondary end points were measures 
of other components of CANTAB. Working mem-
ory was determined on the basis of the spatial 
working memory between-errors score, which 
indicates the number of times a person revisits 
a box in which a token has previously been found 
(scores range from 0 to 279, with lower scores 
indicating fewer errors); episodic memory was 
determined on the basis of the total number of 
errors a patient makes in a paired associates 
learning test, plus an adjustment for the estimated 
number of errors the patients would have made 
on any stages that were not reached (scores 
range from 0 to 70, with lower scores indicating 
fewer errors); and psychomotor speed was deter-
mined on the basis of the median 5-choice reac-
tion time (i.e., the median duration between the 
onset of a stimulus and the release of a button, 
with faster times representing better perfor-
mance).
Between-group differences with respect to the 
primary and secondary end points were assessed 
by a comparison of z scores, with the z score for 
an individual patient representing the difference 
between the score for that patient and the mean of 
the baseline score for all patients, divided by the 
standard deviation of the baseline score for all 
patients. The global composite score of CANTAB 
end points was a prespecified exploratory end 
point and was calculated by averaging the com-
bined z scores of each of the four aforementioned 
CANTAB end points; higher scores indicate better 
performance.
In a prespecified exploratory analysis of every-
day cognitive function at the final visit, patients 
performed self-assessments using a 23-item ques-
tionnaire that represented the executive and 
memory domain subscales of a shortened version 
of the Everyday Cognition (ECog) tool (see the 
Supplementary Appendix).19 For each item, patients 
compared the current level of everyday function-
ing with their retrospective assessment of their 
level at the beginning of the trial (scores ranged 
from 1 to 5, with lower scores representing bet-
ter functioning). Mean overall ECog scores and 
mean scores for each individual domain of the 
ECog questionnaire were compared between study 
groups. Clinical cognitive adverse events were 
categorized according to Medical Dictionary for 
Regulatory Activities (MedDRA) lowest-level terms 
and were compared between the study groups.
Statistical Analysis
The primary-analysis population included patients 
who had a baseline CANTAB assessment before 
or on the day of the first dose of the study drug 
or placebo (which was administered in a blinded 
manner) and had at least one follow-up CANTAB 
assessment. The full-analysis population includ-
ed, in addition, patients whose first CANTAB 
assessment occurred after the day on which the 
first dose of the study drug or placebo was ad-
ministered. Data obtained from patients who had 
a stroke were censored from the analysis after 
the date of stroke onset.
The primary analysis was a noninferiority com-
parison of the mean change in score on the 
spatial working memory strategy index of execu-
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tive function from baseline over time (i.e., the 
difference between the score at baseline and the 
mean score of all assessments after baseline) 
between the patients in the evolocumab group 
and the patients in the placebo group. A mixed-
effects linear model for repeated measures was 
used to estimate treatment differences (the differ-
ence in change in z scores) between study groups, 
with associated 95% confidence intervals. The 
model included the stratification factors, age, 
educational level, score on the baseline spatial 
working memory strategy index, study group, visit, 
and interaction between study group and visit. 
The noninferiority boundary was set at 20% of the 
standard deviation (i.e., Cohen’s d statistic20 <0.20), 
which we estimated from observations in the pla-
cebo group. A two-sided alpha level of 5% was 
used to test for superiority with respect to the 
primary end point. We estimated that a sample 
size of 1500 patients would provide approximate-
ly 97% power to detect noninferiority and 83% 
power to detect superiority. A nominal alpha level 
of 0.05 was used to indicate statistical significance. 
Additional exploratory analyses included all sec-
ondary end-point analyses; subgroup analyses; 
analyses of data according to visit; analyses strati-
fied according to lowest-attained LDL cholesterol 
level of 25 mg per deciliter (0.6 mmol per liter) 
and 40 mg per deciliter (1.0 mmol per liter), 
which were prespecified cutoff points; and analy-
ses in the full-analysis population. All statistical 
computations were performed with the use of 
SAS software, version 9.4 (SAS Institute).
R esult s
Patients
From September 10, 2014, through August 6, 
2015, a total of 2442 patients in the FOURIER trial 
were screened for eligibility for the EBBINGHAUS 
study, and 1974 were enrolled (full-analysis 
population). The baseline characteristics of the 
1204 patients in the primary-analysis population 
were similar in the two study groups (Table 1), 
and the baseline characteristics of the patients in 
the full-analysis population were similar to those 
of the patients in the primary-analysis popula-
tion (Table S1 in the Supplementary Appendix). 
The mean age of the patients was 63 years, 72% 
were men, and participants had a mean of 12.7 
years of education; more than three quarters of 
the patients had previously had a myocardial 
infarction, and one fifth had previously had an 
ischemic stroke. The median LDL cholesterol level 
at the time of randomization was 92 mg per deci-
liter (2.40 mmol per liter); 71% of the patients were 
receiving high-intensity statin therapy and 29% 
were receiving moderate-intensity statin therapy. 
The median duration of follow-up was 19.4 months 
(interquartile range, 19.0 to 21.8) in the primary-
analysis population. Figure S1 in the Supplemen-
tary Appendix shows the randomization and 
follow-up of the full-analysis and primary-analy-
sis populations. One patient in the full-analysis 
population did not receive the study drug and 
did not undergo CANTAB testing after baseline.
Baseline scores for all domains of the CANTAB 
tests were similar in the two study groups in both 
the primary-analysis population (Fig. 1) and the 
full-analysis population (Tables S1 and S2 in the 
Supplementary Appendix). These baseline scores 
were similar to those reported in a population-
based cross-sectional cohort of healthy adults 56 
to 86 years of age.21,22
Outcomes
The mean change from baseline over time in the 
raw score on the spatial working memory strategy 
index of executive function (primary end point) 
did not differ significantly between the two study 
groups; the raw score at baseline was 17.8 in 
both study groups, and the mean (±SD) change 
from baseline in the score was −0.21±2.62 in the 
evolocumab group and −0.29±2.81 in the placebo 
group (P<0.001 for noninferiority [based on the 
z scores] and P = 0.85 for superiority) (Figs. 1 and 2). 
The mean changes in raw scores from baseline 
with respect to the secondary end points did not 
differ significantly between the evolocumab group 
and the placebo group. The raw between-errors 
score on the spatial working memory test at base-
line was 20.9 in the evolocumab group and 21.0 
in the placebo group; the mean changes in score 
from baseline were −0.52±8.15 and −0.93±7.82, 
respectively (P = 0.36 based on the z scores). 
The raw score on the paired associates learning 
test at baseline was 26.5 in the evolocu mab 
group and 25.2 in the placebo group; the mean 
changes in score from baseline were −1.53±12.9 
and −1.53±13.5, respectively (P = 0.49 based on the 
z scores). The raw score on the median 5-choice 
reaction time test at baseline was 356.7 msec in 
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Age — yr 62.8±8.7 62.6±8.6
Male sex — no. (%) 445 (72.0) 420 (71.7)
White race — no. (%)† 572 (92.6) 541 (92.3)
Years of education 12.8±3.4 12.6±3.1
Region — no. (%)
North America 162 (26.2) 153 (26.1)
Europe 411 (66.5) 398 (67.9)
Asia–Pacific and South Africa 45 (7.3) 35 (6.0)
Type of cardiovascular disease — no. (%)‡
Myocardial infarction 468 (75.7) 444 (75.8)
Nonhemorrhagic stroke§ 129 (20.9) 111 (18.9)
Symptomatic peripheral artery disease 101 (16.3) 112 (19.1)
CHA2DS2-VASc score ≥4 — no. (%)¶ 309 (50.0) 324 (55.3)
Neurologic disease that was not stroke — no. (%) 86 (13.9) 86 (14.7)
Hypertension — no. (%) 530 (85.8) 506 (86.3)
Diabetes mellitus — no. (%) 212 (34.3) 218 (37.2)
Current cigarette use — no. (%)‖ 231 (37.4) 185 (31.6)
Atrial fibrillation at any time — no. (%) 62 (10.0) 53 (9.0)
Congestive heart failure — no. (%) 157 (25.4) 176 (30.0)
Statin use — no. (%)
High intensity 454 (73.5) 399 (68.1)
Moderate intensity 164 (26.5) 187 (31.9)
Ezetimibe use — no. (%) 30 (4.9) 32 (5.5)
Use of other cardiovascular medications — no. (%)
Aspirin, P2Y12 inhibitor, or both 556 (90.0) 525 (89.6)
Beta-blocker 459 (74.3) 435 (74.2)
ACE inhibitor or ARB, aldosterone antagonist, or both 472 (76.4) 461 (78.7)
Median LDL cholesterol level (interquartile range) — mg/dl‖** 93 (80–110) 91 (79–108)
*  Plus–minus values are means ±SD. There were no nominally significant differences between the two study groups in 
baseline characteristics except for current cigarette use (P = 0.03) and statin intensity (P = 0.04). ACE denotes angio-
tensin-converting enzyme, ARB angiotensin receptor blocker, and LDL low-density lipoprotein. To convert the values 
for LDL cholesterol to millimoles per liter, multiply by 0.02586.
†  Race was reported by the patient.
‡  Patients could have more than one type of cardiovascular disease.
§  Among the patients who had nonhemorrhagic stroke, the median (interquartile range) number of years from the 
most recent prior stroke was 4.6 (1.4 to 8.8) in the placebo group and 3.6 (1.1 to 8.1) in the evolocumab group.
¶  CHA2DS2-VASc scores, which assess the risk of stroke, range from 0 to 9, with higher scores indicating greater risk; 
points are assigned as follows: congestive heart failure (1 point), hypertension (1 point), 75 years of age or older (2 
points), diabetes mellitus (1 point), prior stroke or transient ischemic attack (2 points), vascular disease (1 point), 65 
to 74 years of age (1 point), and female sex (1 point).
‖  One patient in the placebo group had missing data.
**  LDL cholesterol level was calculated with the use of the Friedewald equation, unless the calculated value was lower 
than 40 mg per deciliter or the measured triglyceride level was higher than 400 mg per deciliter (4.52 mmol per liter), 
in which case ultracentrifugation was performed.
Table 1. Baseline Characteristics of the Patients in the EBBINGHAUS Study with Baseline Cognitive Assessment 
(Primary-Analysis Population).*
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the evolocumab group and 355.1 msec in the 
placebo group; the mean changes in psychomo-
tor speeds from baseline were 5.2±52.7 msec 
and 0.9±63.9 msec, respectively (P = 0.06 based 
on the z scores). The global composite z score at 
baseline was −0.015 in the evolocumab group 
and −0.002 in the placebo group; changes in 
global composite z scores were 0.031±0.411 and 
0.061±0.454, respectively (P = 0.12). An analysis 
of outliers (poorest scores) did not show signifi-
Figure 1. Primary and Secondary Cambridge Neuropsychological Test Automated Battery (CANTAB) End Points.
Panel A shows the unadjusted raw scores on the spatial working memory strategy index of executive function (the 
primary end point). The score indicates the number of times a patient begins a search with a different box than the 
one used to begin the search in the previous search sequence, across a total of four rounds of testing that have 6 or 
8 boxes; scores range from 4 to 28, with lower scores representing a more efficient use of strategy and planning. 
Apparent discrepancies in change values are due to rounding of raw scores. Panels B through D show the raw scores 
for three secondary end-point assessments. Panel B shows the raw scores for working memory as assessed by the 
spatial working memory between-errors test, which indicates the number of times a person revisits a box in which a 
token has previously been found; scores range from 0 to 279, with lower scores indicating fewer errors. Panel C shows 
the raw scores for episodic memory, which is determined of the basis of the total number of errors a patient makes 
in a paired associates learning test, plus an adjustment for the estimated number of errors the patient would have 
made on any stages that were not reached; scores range from 0 to 70, with lower scores indicating fewer errors. 
Panel D shows the raw scores for psychomotor speed, which is determined on the basis of the median 5-choice reac-
tion time (i.e., the median duration between the onset of a stimulus and the release of a button); faster times repre-
sent better performance. All scores are shown for the primary-analysis population (all patients who had a baseline 
CANTAB assessment before or on the same day as the first dose of study drug or placebo). The first pair of bars 
represents the mean scores obtained at baseline; the second pair of bars, the means of all scores obtained at the 
postbaseline assessments; and the third pair of bars, the change in scores over time (i.e., the difference between 
the score at baseline and the mean score of all assessments after baseline). Negative numbers of change represent 
improvement in performance as compared with the baseline score. T bars represent one standard deviation from the 
mean. There were no significant differences between evolocumab and placebo in any of the pairwise comparisons.
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cant differences between the study groups (Ta-
ble S3 in the Supplementary Appendix).
The scores for the individual CANTAB end 
points and the global composite score of CANTAB 
end points at each visit were similar in the study 
groups throughout the trial. Results in the full-
analysis population showed no significant differ-
ences between the study groups in the four indi-
vidual CANTAB end points or in the global 
composite score of CANTAB end points. (See Figs. 
S2 and S3 and Table S2 in the Supplementary 
Appendix.)
The mean changes in scores from baseline 
were similar within study groups, when patients 
were stratified according to the lowest-attained 
LDL cholesterol level across the prespecified LDL 
cholesterol cutoff points (including 661 patients 
in the evolocumab group who had an LDL choles-
terol level <25 mg per deciliter). The mean chang-
es from baseline were also similar between the 
study groups, when patients were stratified ac-
cording to the lowest-attained LDL cholesterol 
level (Table 2).
Subgroup Analysis
The cognitive test results in prespecified sub-
groups were consistent with the results in the 
overall population. An exploratory analysis of 
the primary end point, with stratification accord-
ing to the final screening LDL cholesterol level 
(≥85 vs. <85 mg per deciliter), suggested that the 
primary end point favored placebo among the 
patients with a baseline LDL cholesterol level 
lower than 85 mg per deciliter, whereas it favored 
evolocumab among patients with a baseline LDL 
cholesterol level of 85 mg per deciliter or higher 
(P = 0.01 for interaction, without adjustment for 
multiple comparisons). However, an analysis of 
the secondary end points did not provide further 
supportive evidence for treatment modification 
according to baseline LDL cholesterol level. Fur-
thermore, a post hoc analysis of the changes with 
respect to the primary and secondary end points, 
stratified according to quartiles of LDL choles-
terol levels at baseline, suggested that the spatial 
working memory scores in the placebo group in 
the quartile with the lowest LDL cholesterol level 
(<80 mg per deciliter [2.1 mmol per liter]) may 
have been an outlier, because there was no con-
sistent directional relationship between LDL cho-
lesterol level and the primary end point. (Addi-
tional details on the results of the subgroup 
analyses are provided in Figs. S4 through S6 in 
the Supplementary Appendix.)
Self-Assessment of Everyday Cognition
A total of 1581 patients in the EBBINGHAUS 
study, which included 946 patients in the primary-
Figure 2. Change in z Scores with 95% Confidence Intervals for the Primary and Secondary CANTAB End Points  
and the Global Composite Score of CANTAB End Points.
Shown is the difference in change in z scores between the placebo group and the evolocumab group, based on the 
linear mixed model, of the spatial working memory strategy index of executive function (primary end point), in the 
primary-analysis population. Also shown are the between-group differences in the changes over time for three sec-
ondary CANTAB end points (spatial working memory between-errors score, paired associates learning total errors 
adjusted score, and median 5-choice reaction time) and for the global composite score of CANTAB end points. The 
noninferiority margin for the primary end point was 0.19 (20% of the standard deviation of change from baseline in 
z score in the placebo group). The P value for the noninferiority of the primary end point (based on the z scores) 
was <0.001, and the P value for superiority was 0.85. The P values for the three secondary CANTAB end points and 
the global composite score of CANTAB end points, as calculated by means of a two-sided superiority test for adjusted 
treatment difference using the linear mixed model, were 0.36, 0.49, 0.06, and 0.12, respectively.
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index of executive function score
Secondary end points
Spatial working memory between-errors score
Paired associates learning total errors adjusted score
Median 5-choice reaction time
Exploratory end point: global composite score
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End Point Lowest-Attained LDL Cholesterol Level











Primary end point: executive function (spatial 
working memory strategy index of 
 executive function raw score)†
No. of patients with data 639 199 103 12 924
Change in score over time −0.2±2.7 −0.3±2.9 −0.4±2.6 0.7±2.2 −0.4±3.0
Secondary end points
Working memory (spatial working memory 
between-errors raw score)‡
No. of patients 639 199 103 12 924
Change in score over time −0.5±8.7 0.2±9.6 −0.8±8.1 0.4±9.1 −0.6±8.3
Episodic memory (paired associates learning 
raw score adjusted)§
No. of patients 638 199 103 12 919
Change in score over time −0.3±14.5 −0.6±12.3 −1.0±12.9 −3.4±18.0 −0.2±14.6
Psychomotor speed (median 5-choice  
reaction time raw score)¶
No. of patients 632 199 102 12 914
Change in score (in milliseconds)  
over time
5.5±55.7 1.4±66.2 7.8±54.6 0.3±65.1 1.8±60.3
Exploratory end point: global composite score  
of CANTAB end points‖
No. of patients 638 199 103 12 922
Change in z score over time 0.02±0.44 0.02±0.42 0.03±0.40 −0.02±0.44 0.04±0.47
*  Plus–minus values are means ±SD changes from baseline over time (i.e., the difference between the mean score at baseline and the mean 
score of all assessments after baseline). With respect to the change values for the primary and secondary end points, negative numbers in-
dicate an improvement in score over time. With respect to change values in the global composite score, positive numbers indicate an im-
provement over time. For patients who had a stroke after randomization, the final assessment was the last assessment before the stroke. 
Negative changes in raw score (i.e., a lower value) indicate improvement over time. Positive changes in z score indicate improvement over 
time. None of the comparisons between study groups or across strata of lowest-attained LDL cholesterol level were significant (P>0.05 for 
each comparison). CANTAB denotes Cambridge Neuropsychological Test Automated Battery. Six patients in the placebo group who had a 
lowest-attained LDL cholesterol level lower than 25 mg per deciliter were not included in the table because this was too small of a group to 
analyze. An additional four patients in the placebo group had no data for either CANTAB end points or LDL cholesterol level after random-
ization.
†  The score indicates the number of times a patient begins a search with a different box than the one used to begin the search in the previous 
search sequence, across a total of four rounds of testing that have 6 or 8 boxes; scores range from 4 to 28, with lower scores representing a 
more efficient use of strategy and planning.
‡  The score indicates the number of times a person revisits a box in which a token has previously been found; scores range from 0 to 279, 
with lower scores indicating fewer errors.
§  The score indicates the total number of errors a patient makes in a paired associates learning test, plus an adjustment for the estimated 
number of errors the patients would have made on any stages that were not reached; scores range from 0 to 70, with lower scores indicat-
ing fewer errors.
¶  The score indicates the median duration (in milliseconds) between the onset of a stimulus and the release of a button; faster times repre-
sent better performance.
‖  The global composite score was a prespecified exploratory end point and was calculated by averaging the combined z scores of each of the 
four CANTAB end points.
Table 2. Changes in CANTAB End Points and Global Composite Score of CANTAB End Points, Stratified According to Lowest-Attained LDL 
Cholesterol Level (Full-Analysis Population).*
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analysis population, completed the ECog ques-
tionnaire at the end of the study. No significant 
between-group differences were observed in the 
scores on the individual domains or in the total 
score (the mean total score was 1.13 in the pla-
cebo group and 1.14 in the evolocumab group; 
P = 0.42). A comparison of the percentage of pa-
tients who reported various levels of decline in 
cognition showed no significant differences be-
tween study groups. (See Tables S4 and S5 in the 
Supplementary Appendix.)
Cognitive Adverse Events
Cognitive adverse events, which included memo-
ry or concentration difficulty occurred in 11 of 
586 patients (1.9%) in the evolocumab group 
and in 8 of 618 patients (1.3%) in the placebo 
group in the primary-analysis population. In the 
full-analysis population, cognitive adverse events 
occurred in 19 of 983 patients (1.9%) in the evo-
locumab group and in 16 of 990 patients (1.6%) 
in the placebo group (Table S6 in the Supple-
mentary Appendix).
Discussion
This study evaluated cognition in 1974 patients 
from the FOURIER trial, a double-blind, placebo-
controlled trial of the PCSK9 inhibitor evolocu-
mab in patients with stable atherosclerotic car-
diovascular disease. No significant differences 
in cognitive function test scores or in subjective 
self-assessments of everyday cognition were ob-
served between the patients in the evolocumab 
group and those in the placebo group. Evolocu-
mab, as compared with placebo, neither improved 
nor worsened executive function, working mem-
ory, episodic memory, or psychomotor speed, as 
assessed with the use of CANTAB, an established 
tablet-based tool, over a median follow-up of 19 
months. To give perspective to the measures of 
cognitive testing with CANTAB in this study, we 
note that the changes seen over time in each 
study group were an order of magnitude less 
than the changes found in patients with mild 
cognitive impairment preceding dementia,23 in 
patients who have received a therapeutic dose of 
a benzodiazepine,24 and in persons with blood 
alcohol concentrations of 50 mg per deciliter.24 
Furthermore, no significant between-group differ-
ences were observed at the end of the study in 
the patients’ self-assessment of memory, planning, 
organization, or attention.
The findings from the 60 prespecified sub-
group analyses (12 subgroups across the five end 
points) were consistent with the main findings, 
with two exceptions — the analysis of the pri-
mary end point that was dichotomized accord-
ing to screening LDL cholesterol level and the 
analysis of reaction time that was stratified ac-
cording to the presence or absence of a neuro-
logic disorder that was not a stroke; both showed 
evidence of significant subgroup–treatment effect 
heterogeneity. Given the large number of sub-
groups analyses that were performed, the absence 
of a monotonic relationship in an analysis of 
primary and secondary end points stratified ac-
cording to quartile of LDL cholesterol level at the 
final screening visit, and the lack of similar 
findings across the other subgroups, the two 
exceptions may have been due to chance. Explor-
atory analyses of the CANTAB assessments that 
were stratified according to the lowest-attained 
LDL cholesterol level after randomization did not 
show associations between LDL cholesterol level 
and adverse cognitive outcomes, including among 
the 661 patients whose lowest-attained LDL cho-
lesterol levels were below 25 mg per deciliter.
A meta-analysis of phase 2 and phase 3 trials 
of evolocumab and a drug in the same class, 
alirocumab, showed an association between the 
use of PCSK9 inhibitors and a higher risk of 
cognitive adverse events than with the control.11 
An analysis of prespecified cognitive adverse events 
among 27,564 patients enrolled in the parent 
FOURIER trial of the efficacy and safety of evo-
locumab showed no significant difference be-
tween evolocumab and placebo.3
Our study has several limitations. The follow-
up period was short, and patients with known 
dementia or mild cognitive impairment were ex-
cluded. However, two other studies that showed a 
putative association between statins and adverse 
cognitive effects were only 6 months in duration.4,5 
An ongoing 5-year extension of the FOURIER 
trial includes CANTAB assessments in approxi-
mately 500 patients who had also participated in 
EBBINGHAUS and will provide longer-term data 
regarding cognition (ClinicalTrials.gov number, 
NCT02867813). Nevertheless, even longer studies 
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on the use of PCSK9 inhibitors25 as well as other 
lipid-lowering therapies are desirable, because 
patients with elevated cholesterol levels are typi-
cally treated for decades. Another possible limita-
tion is that the use of the tablet-based CANTAB 
tool is not standard in clinical practice or lipid 
research; however, it has been validated as a re-
search tool,26-29 is sensitive to change over time,23,30,31 
and was cleared by the Food and Drug Adminis-
tration as a tool to detect memory impairment.32 
Although there is no accepted threshold for 
changes in cognitive function in the scores used 
in the tool, the magnitude of the noninferiority 
boundary that we selected is similar to that ex-
pected over a 6-year period of normal aging in a 
cohort21 of patients with ages similar to those of 
the patients in the EBBINGHAUS population. 
Furthermore, the observed upper bound of the 
95% confidence interval extended to less than 
half the distance to the noninferiority boundary. 
Finally, self-assessments of everyday cognition 
with the use of the ECog questionnaire were not 
obtained at the start of the trial, and subjective 
assessment of change may be subject to recall 
bias. The absence of a difference in self-reported 
clinical changes in cognition at the end of the 
trial supports the results of cognitive function 
testing and suggests that a large decline in cog-
nition was not missed.
In conclusion, among patients who received 
either the PCSK9 inhibitor evolocumab or pla-
cebo in addition to statin therapy, we did not 
find an association between adverse cognitive 
effects and evolocumab, as compared with pla-
cebo, over a median of 19 months, even among 
patients who attained very low levels of LDL 
cholesterol.
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